BioTissue Ocular

Home
United States
Miami, FL
BioTissue Ocular

We develop innovative Amniotic Membrane products for the management of ocular surface diseases.

BioTissue® is the leader in regenerative biologic therapies and ocular hygiene solutions, helping eye care professionals heal ocular surface conditions, such as keratitis, recurrent corneal erosions, conjunctivochalasis dry eye, pterygium and dry eye.

09/09/2026

What a week in Québec City!

The BioTissue® team joined the ALLDOCS Annual Meeting, connecting with eye care professionals and sharing insights on ocular surface care and BioTissue products, including
CAM360 AmnioGraft™ and Prokera®.

Thank you to everyone who spent time with our team and contributed to the thoughtful conversations throughout the week. We enjoyed connecting with you!

09/03/2026

Our event calendar is filling up, and the BioTissue® team is hitting the road!

From London to Anaheim and on to New Orleans, our team is looking forward to connecting with eye care professionals at:
- European Society of Cataract and Refractive Surgeons (ESCRS)
- Academy 2026 Anaheim (American Academy of Optometry)
- ASOPRS Fall Scientific Symposium
- AAO Annual Meeting

Will our paths cross? Follow along for event updates and details on where to connect with us.

09/01/2026

We are proud to present Chris Calcaterra as a new member of BioTissue®’s Board of Directors!

Chris brings decades of experience in ophthalmology and a strong track record of driving innovation, growth, and physician engagement across the eye care industry.

His expertise will bring valuable perspective as BioTissue continues to advance its focus on ocular health and expand our impact in eye care.

We’re excited to have Chris with us as we continue to grow as the trusted source in ocular health.

Learn more: https://brnw.ch/21x5mzY

08/28/2026

We're looking forward to seeing you at ALLDOCS!

Stop by to connect with the BioTissue® team and learn how CAM360 AmnioGraft™ and Prokera® may help support your approach to ocular surface care. Whether you're already partnering with us or exploring new treatment options, we're here to help you get the most from your partnership!

We can't wait to see you there!

08/26/2026

We’re honored to once again support the Women in Ophthalmology Summer Symposium.

Celebrating the women who are leading, mentoring, innovating, and shaping the future of ophthalmology is something we're proud to be part of. Thank you to everyone who shared their time and insights with our team. We can’t wait to see what the year ahead brings.

08/21/2026

Every patient story has the power to inspire awareness.
During Stevens-Johnson Syndrome (SJS) Awareness Month, we're sharing Amberle's journey to help shine a light on a rare but serious condition that can affect both the skin and eyes.

Her story is a reminder of the importance of early recognition, timely care, and continued advances in ocular healing. At BioTissue®, we're proud to support physicians with Cryopreserved Amniotic Membrane (CAM) treatment options to help care for patients with ocular surface disorders.

Together, awareness can help lead to better outcomes.

08/20/2026

Study Spotlight: In a prospective, randomized controlled clinical study of patients with moderate to severe dry eye disease (DED), a single placement of Prokera® was shown to accelerate healing of the ocular surface.

Treatment with cryopreserved amniotic membrane (CAM) significantly increased corneal nerve density while significantly reducing signs and symptoms of DED, with sustained reduction in dry eye for up to at least 3-months.

Evidence matters.
Read the full study: https://doi.org/10.1155/2017/6404918

John T, Tighe S, Sheha H, Hamrah P, Salem ZM, Cheng AMS, Wang MX, Rock ND. Corneal nerve regeneration after self-retained cryopreserved amniotic membrane in dry eye disease. J Ophthalmol. 2017;2017:6404918. doi:10.1155/2017/6404918

08/17/2026

We’re honored to once again participate in the Women in Ophthalmology Summer Symposium.

We look forward to joining this incredible community in Monterey, California, connecting with colleagues, sharing ideas, and supporting the continued advancement of ophthalmology.

We can’t wait to see you there!

08/13/2026

Def(eye)ning the standard with an average of 1 to 1.1 Cryopreserved Amniotic Membrane (CAM) placements reported across published studies evaluating CAM for the treatment of Dry Eye Disease.¹⁻²

Grounded in published clinical evidence, CAM continues to support physicians in the management of ocular surface disease.

1. McDonald, M, Janik, SB, Bowden, FW. et al. Association of Treatment Duration and Clinical Outcomes in Dry Eye Treatment with Sutureless Cryopreserved Amniotic Membrane. Clin Ophthalmol. 2023;Sep 12:17:2697- 2703.

2. John T, Tighe S, Sheha H, Hamrah P, Salem ZM, Cheng AMS, Wang MX, Rock ND. Corneal nerve regeneration after self-retained cryopreserved amniotic membrane in dry eye disease. J Ophthalmol. 2017;2017:6404918. doi:10.1155/2017/6404918.

08/11/2026

SJS is a rare but serious condition that can affect both the skin and eyes. Because ocular involvement is common during the acute phase, early recognition and timely ophthalmic evaluation are important to help protect vision.¹

At BioTissue®, we're proud to support the ophthalmic community through education, innovation, and a commitment to improving patient care.

This month, we join healthcare professionals in raising awareness of SJS and the importance of early intervention to help improve outcomes.

1. Kumar MJ Jr, et al. Cureus. 2024 Jul 29;16(7):e65693.

Address

7300 Corporate Center Drive, Suite 700
Miami, FL
33126

Website

http://www.biotissue.com/products/BioTissue-ocular/

Alerts

Be the first to know and let us send you an email when BioTissue Ocular posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Want your practice to be the top-listed Clinic in Miami?